Kiniksa Pharmaceuticals Ltd (KNSA)

Currency in USD
30.06
-0.31(-1.02%)
Closed·
After Hours
30.05-0.01(-0.03%)
·

KNSA Financial Summary

Key Ratios

P/E Ratio459.9
Price/Book4.83
Debt / Equity1.97%
Return on Equity1.03%
Dividend Yield0.00%
EBITDA-43.92M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of USD (except for per share items)

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 41.17
(+36.95% Upside)

Earnings

Latest Release
Jul 29, 2025
EPS / Forecast
0.23 / 0.19
Revenue / Forecast
156.79M / 145.28M
EPS Revisions
Last 90 days

FAQ

What were Kiniksa Pharma's earnings for the latest quarter?

The Kiniksa Pharma EPS (TTM) is 0.07. Kiniksa Pharma reported sales of 156.80, net income of 17.83, and EPS of 0.23 for the latest quarter.

What was Kiniksa Pharma's net income for the latest quarter?

Kiniksa Pharma's net income for the latest quarter was 17.83.

How did Kiniksa Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 137.79 in the previous quarter to 156.80 in the latest quarter, and net income moved from 8.54 to 17.83 compared to the previous quarter.

What is Kiniksa Pharma's net profit margin on a TTM basis?

Kiniksa Pharma's trailing twelve months (TTM) net profit margin is -10.21%.

How does Kiniksa Pharma's debt to equity ratio compare to industry standards?

Kiniksa Pharma's total debt-to-equity ratio is 1.97%.

What is Kiniksa Pharma's return on investment on a TTM basis?

Kiniksa Pharma's trailing twelve months (TTM) return on investment (ROI) is 1.03%.

Did Kiniksa Pharma gain or lose cash last quarter?

In the latest quarter, Kiniksa Pharma's net change in cash was 34.91 million.

What were Kiniksa Pharma's total assets and liabilities in the latest quarter?

As of the latest quarter, Kiniksa Pharma reported total assets of 661.15 million and total liabilities of 117.83 million.

How has Kiniksa Pharma's total revenue grown this year?

Kiniksa Pharma's total revenue was 137.79 in the previous quarter and 156.80 in the latest quarter.

What is Kiniksa Pharma's gross margin on a TTM basis?

Kiniksa Pharma's trailing twelve months (TTM) gross margin is 54.38%.

What was Kiniksa Pharma's revenue per share for the latest quarter?

Kiniksa Pharma's revenue per share for the latest quarter was 43.97.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.